We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+34.4%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$3.43B
AUM Growth
+$283M
(+9%)
Cap. Flow
-$809M
Cap. Flow
% of AUM
-23.57%
Top 10 Holdings %
Top 10 Hldgs %
38.81%
Holding
112
New
24
Increased
11
Reduced
35
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$67.2M |
| 2 |
Larimar Therapeutics
LRMR
|
+$59.9M |
| 3 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$29.8M |
| 4 |
GBIO
Generation Bio
GBIO
|
+$26.4M |
| 5 |
RNAM
Avidity Biosciences
RNAM
|
+$25.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AdaptHealth
AHCO
|
+$264M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$168M |
| 3 |
Q32 Bio
QTTB
|
+$62.7M |
| 4 |
ABMD
Abiomed Inc
ABMD
|
+$54.6M |
| 5 |
IMMU
Immunomedics Inc
IMMU
|
+$45.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 65.56% |
| 2 | Financials | 0.55% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Protagonist Therapeutics
PTGX
$8.92B
| $17.9M | 0.52% |
+1,013,495
| New | +$12.7M |
|
52
Ardelyx
ARDX
$1.28B
| $17.7M | 0.52% |
2,561,554
-521,446
| -17% | -$3.62M |
|
|
ADVM
53
DELISTED
Adverum Biotechnologies
ADVM
| $17.4M | 0.51% |
83,390
-124,110
| -60% | -$22M |
|
54
Natera
NTRA
$37.9B
| $16.2M | 0.47% |
324,038
-991,962
| -75% | -$39.8M |
|
|
SIEN
55
DELISTED
Sientra, Inc.
SIEN
| $16.1M | 0.47% |
416,280
-6,488
| -2% | -$196K |
|
|
LUMO
56
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $15.4M | 0.45% |
936,169
| – | – |
|
57
Cerus
CERS
$637M
| $14.6M | 0.42% |
2,204,700
| – | – |
|
58
Protara Therapeutics
TARA
$229M
| $12.7M | 0.37% |
432,670
| – | – |
|
|
TPTX
59
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $12.2M | 0.35% |
188,490
-224,831
| -54% | -$13M |
|
60
Enliven Therapeutics
ELVN
$3.76B
| $11.7M | 0.34% |
106,000
-19,000
| -15% | -$2.13M |
|
|
ACH
61
Accendra Health
ACH
$258M
| $11.3M | 0.33% |
+1,477,000
| New | +$10.8M |
|
62
Keros Therapeutics
KROS
$211M
| $11.3M | 0.33% |
+300,000
| New | +$9.24M |
|
|
OXFD
63
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $11M | 0.32% |
845,000
+690,604
| +447% | +$8.3M |
|
64
Oric Pharmaceuticals
ORIC
$1.11B
| $10.1M | 0.29% |
+300,000
| New | +$9.58M |
|
|
APLT
65
DELISTED
Applied Therapeutics
APLT
| $10.1M | 0.29% |
278,359
| – | – |
|
|
ITMR
66
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
| $9.28M | 0.27% |
499,136
| – | – |
|
67
Xeris Biopharma Holdings
XERS
$1.5B
| $8.46M | 0.25% |
3,178,551
-254,740
| -7% | -$887K |
|
|
SEM
68
DELISTED
Select Medical
SEM
| $8.32M | 0.24% |
1,048,640
-924,288
| -47% | -$7.66M |
|
69
Spyre Therapeutics
SYRE
$8.68B
| $7.63M | 0.22% |
+33,000
| New | +$6.28M |
|
|
AERI
70
DELISTED
Aerie Pharmaceuticals
AERI
| $7.29M | 0.21% |
494,216
-2,037,931
| -80% | -$30.1M |
|
|
AKUS
71
DELISTED
Akouos Inc
AKUS
| $7.16M | 0.21% |
+318,034
| New | +$7.09M |
|
|
ARYBU
72
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
| $5.8M | 0.17% |
+500,000
| New | +$5.5M |
|
|
MNK
73
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $5.28M | 0.15% |
1,970,687
-2,056,063
| -51% | -$6.17M |
|
74
Cabaletta Bio
CABA
$458M
| $5.17M | 0.15% |
464,252
-820,061
| -64% | -$6.28M |
|
75
Neuronetics
STIM
$134M
| $3.27M | 0.1% |
1,693,317
+118,317
| +8% | +$243K |
|
Similar funds
FT
GRQ
PCM
VA
QC
IC
NW
AAF
Deerfield Management's Q2 2020 Portfolio in Review
As of Q2 2020, Deerfield Management held 112 positions worth $3.43B, up 9% from $3.15B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Deerfield Management withdrew a net $809M in Q2 2020, closing 19 positions and reducing 35 holdings. Its most notable exit was Q32 Bio, an estimated $62.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 72% a quarter earlier, followed by Financials and Technology.
Against the trend, Deerfield Management opened a new position in Hologic worth $78.1M.
- Deerfield Management's largest Q2 2020 buy was Hologic: 1,370,186 shares worth $78.1M.
- Deerfield Management added most to MyoKardia, Inc. Common Stock in Q2 2020, an estimated $29.8M increase.
- Deerfield Management's biggest Q2 2020 reduction was AdaptHealth, cutting an estimated $264M.
- Deerfield Management fully exited Q32 Bio in Q2 2020, selling an estimated $62.7M.
- Deerfield Management's ten largest holdings make up 39% of its $3.43B portfolio in Q2 2020.
- Deerfield Management opened 24 new positions and closed 19 in Q2 2020.
- Deerfield Management's portfolio value rose 9% quarter-over-quarter to $3.43B.
Based on Deerfield Management's 13F filing for Q2 2020, filed 14 Aug 2020.